Review on recommendations on the use of biologic therapy for the management of moderate-severe psoriasis in Saudi Arabia: an expert opinion.

IF 4 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-24 DOI:10.1080/14712598.2025.2495986

Mohammed Fatani, Abdullah Aldugaither, Mufaddal Alaithan, Amaal Alruwaili, Sultan Mubarki, Mohammed Alajlan, Yousef Binamer, Aymen Alharbi, Bedor AlOmari, Issam Hamada

{"title":"Review on recommendations on the use of biologic therapy for the management of moderate-severe psoriasis in Saudi Arabia: an expert opinion.","authors":"Mohammed Fatani, Abdullah Aldugaither, Mufaddal Alaithan, Amaal Alruwaili, Sultan Mubarki, Mohammed Alajlan, Yousef Binamer, Aymen Alharbi, Bedor AlOmari, Issam Hamada","doi":"10.1080/14712598.2025.2495986","DOIUrl":null,"url":null,"abstract":"Introduction: Psoriasis is a chronic inflammatory skin disorder with a significant global burden, impacting patients both physically and psychologically. While its exact etiology remains unclear, genetic predisposition and environmental triggers play key roles.Areas covered: Biologic therapies have revolutionized psoriasis management, offering targeted and effective disease control. However, despite their proven benefits, these treatments remain underutilized, limiting optimal outcomes and contributing to disparities in care. This expert consensus examines current challenges in biologics use and provides evidence-based recommendations for managing moderate-to-severe psoriasis in Saudi Arabia.Expert opinion: Optimizing biologic therapy use is crucial for improving patient outcomes and reducing disease burden. By addressing gaps in clinical practice, this consensus aims to streamline management approaches and reduce treatment disparities in Saudi Arabia.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"599-606"},"PeriodicalIF":4.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2025.2495986","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disorder with a significant global burden, impacting patients both physically and psychologically. While its exact etiology remains unclear, genetic predisposition and environmental triggers play key roles.

Areas covered: Biologic therapies have revolutionized psoriasis management, offering targeted and effective disease control. However, despite their proven benefits, these treatments remain underutilized, limiting optimal outcomes and contributing to disparities in care. This expert consensus examines current challenges in biologics use and provides evidence-based recommendations for managing moderate-to-severe psoriasis in Saudi Arabia.

Expert opinion: Optimizing biologic therapy use is crucial for improving patient outcomes and reducing disease burden. By addressing gaps in clinical practice, this consensus aims to streamline management approaches and reduce treatment disparities in Saudi Arabia.

查看原文本刊更多论文

沙特阿拉伯中重度牛皮癣生物治疗建议综述：专家意见

简介：牛皮癣是一种慢性炎症性皮肤病，具有显著的全球负担，影响患者的身体和心理。虽然其确切的病因尚不清楚，但遗传易感性和环境触发因素起着关键作用。涵盖领域：生物疗法彻底改变了牛皮癣的管理，提供了有针对性和有效的疾病控制。然而，尽管这些治疗方法已被证实有益，但它们仍未得到充分利用，限制了最佳结果，并造成了护理方面的差异。这份专家共识审查了目前在生物制剂使用方面面临的挑战，并为沙特阿拉伯管理中重度牛皮癣提供了循证建议。专家意见：优化生物疗法的使用对于改善患者预后和减轻疾病负担至关重要。通过解决临床实践中的差距，这一共识旨在简化管理方法并减少沙特阿拉伯的治疗差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.